A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or P13K-Delta Inhibitor Therapy
Administered By
Awarded By
Contributors
- Brander, Danielle Marie Principal Investigator
Start/End
- September 1, 2016 - September 1, 2022